ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC by Dr. Edward Garon

Article

GALAXY-1 TrialDr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

 

[powerpress]

Dr. Ross Camidge on ALK Inhibition, Molecular Screening, and Options after XALKORI

Article

Continuing with Dr. Ross Camidge as our focus (see yesterday's post for a brief update from him on the afatinib/cetuximab trial), today let's turn to the recent webinar program he and Dr. Ben Solomon did with us on the subject of ALK Inhibition: From Biology to FDA-Approved Therapy for Advanced NSCLC". After Dr.

HSP 90 Inhibitors: Another Rational Choice for Patients with Acquired Resistance to EGFR Inhibitors

Article

Continuing Dr. West's theme discussing new therapies for patients with acquired resistance, I'd like to answer a few questions about HSP 90 inhibitors that have caught my attention on GRACE over the past few weeks, and in particular, highlight my "pet" targeted agent, AUY922. HSP 90 inhibitors are drugs that many of you already know about-they are being studied in patients with ALK(+)lung cancer and as a 2nd line therapy option for all patients with lung cancer with Taxotere.